Signed, Sealed, Delivered:
Evolving Treatment Options for the Management of Perianal Fistula in Crohn’s Disease

Tuesday, November 22, 2022
8p ET / 7p CT / 6p MT / 5p PT

Zoom Webinar & Small Group Discussion

Certification period for this program has expired.

No credit will be offered beyond the program dates noted on the bottom of this page.

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE in partnership with MondayNightIBD.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A. Inc.

Program Overview

When perianal fistulas (PAF) develop in Crohn’s disease (CD), poor long-term outcomes in patients with CD can be predicted. There are many identifiable gaps regarding the treatment of PAF in CD, and it is important to update clinicians on the current state of PAF in CD epidemiology, management best practices, and evolving treatment options.

This CME-certified, live Zoom-based webinar discussion will focus on the epidemiology of PAF in CD, as well as prognosis, burden, treatment goals and management. A portion of the webinar will be dedicated to focusing on the patient perspective.

Faculty

Aline Charabaty, MD, AGAF, FACG
Assistant Clinical Director of the Division of Gastroenterology
Johns Hopkins School of Medicine
Clinical Director of IBD
Johns Hopkins - Sibley Memorial Hospital
Washington, DC

Marla Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Director, Marie and Barry Lipman IBD Preconception and Planning Clinic
Mount Sinai Kravis Children’s Hospital
Icahn School of Medicine Mount Sinai New York
New York, NY

Stefan D. Holubar, MD, MS, FACS, FASCRS
IBD Surgery Section Chief
Director of Research
Dept. of Colorectal Surgery
Cleveland Clinic
Cleveland, OH

Tina Aswani-Omprakash
Patient Advocate
Co-founder, South Asian IBD Alliance (SAIA)
New York, NY

Target Audience

This program is intended for gastroenterologists, surgeons, pharmacists, nurses, nurse practitioners, physician associates/physician assistants, and internists.

Learning Objectives

After completing this activity series, learners should be better able to:

  • Describe the healthcare burden and psychosocial effects of PAF on patients with CD to improve outcomes

  • Distinguish current best practices for the management of PAF

  • Assess data gaps and the need to establish studies evaluating management of patients with treatment refractory disease

  • Evaluate current and emerging treatment options for patients with PAF in CD

Disclosures of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

  • Aline Charabaty, MD, AGAF, FACG
    Consultant/Advisor/Speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Takeda

    Marla Dubinsky, MD
    Consultant/Advisor/Speaker: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus Biosciences, Takeda

    Stefan D. Holubar, MD, MS, FACS, FASCRS
    Consultant/Advisor/Speaker: Guidepoint, Shionogi, Takeda

    Tina Aswani-Omprakash
    Consultant/Advisor/Speaker: AbbVie, Arena Pharmaceuticals/Pfizer, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Genentech/Roche, Hollister Inc., Janssen, Takeda

  • PACE, Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Joint Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

Release date: November 22, 2022
Expiration date: November 22, 2023
Estimated time to complete activity: 75 minutes